Company news
Atossa Therapeutics, Inc. news in 2023
Atossa Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
December 3, 2023
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
November 19, 2023
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 12, 2023
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
November 8, 2023
Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
September 17, 2023
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 13, 2023
Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023
August 7, 2023
Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada
July 19, 2023
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
July 9, 2023
Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer
July 5, 2023
Atossa Therapeutics announces 30% enrollment for Phase 2 I-Spy breast cancer clinical trial
June 27, 2023
Atossa Therapeutics Announces $10M Stock Repurchase Program
June 26, 2023
Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023
June 21, 2023
Atossa Therapeutics announces further patent protection for Endoxifen
June 20, 2023
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
June 11, 2023
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
May 31, 2023
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 14, 2023
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update
March 21, 2023
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial
March 20, 2023
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
February 22, 2023